Showing 2551-2560 of 19323 results for "".
Evaluating Structured Interventions for Cognitive Support in MS
https://reachmd.com/programs/Audioabstracts/structured-interventions-cognitive-support-ms/54242/For patients with multiple sclerosis (MS), cognitive impairment can quietly erode independence and quality of life. In this AudioAbstract, Dr. Hallie Blevins discusses a head-to-head comparison of cognitive training, aerobic exercise, and a combined approach and explores how we can better support coInnovation in Androgenetic Alopecia
https://reachmd.com/series/c-suite-chats/innovation-in-androgenetic-alopecia/54265/Diana Harbort, President of Cosmo Pharmaceuticals' Dermatology Division, discusses the need for new innovations in androgenetic alopecia and the promise of clascoterone for treating the condition.Expert Opinions on Characteristics of Patients With IgA Nephropathy (IgAN) at High Risk of Progression
https://reachmd.com/programs/medical-industry-feature/igan-high-risk-progression-characteristics/39256/In patients with IgA nephropathy (IgAN), pathological findings can help provide important prognostic information beyond clinical context. Drs Dana Rizk, Sanjeev Sethi, Leal C. Herlitz, and Carla Nester provide expert insights on integrating these findings with clinical and demographic data to assessUnderstanding the Growing Impacts of Obesity on Patient Outcomes and Care Delivery
https://reachmd.com/programs/clinicians-roundtable/understanding-the-growing-impacts-of-obesity-patient-outcomes-and-care-delivery/39652/With obesity rates rising to unprecedented levels, clinicians face critical challenges in managing associated complications. Hear from Dr. Sujith Cherian as he explores obesity’s systemic impact, from cardiovascular and infectious risks to medication dosing and hospital care complexities. Dr.Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://reachmd.com/series/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validaIL-31’s Role in Prurigo Nodularis
https://reachmd.com/series/dermatology-hub-neuroimmune-network/il-31s-role-in-prurigo-nodularis/48804/Raj Chovatiya, MD, PhD, MSCI, FAAD, explains the role of the IL-31 pathway in neuroinflammatory disease such as prurigo nodularis.Effector Cell Response Inhibitors
https://reachmd.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urImproving Care Options for CTCL
https://reachmd.com/series/c-suite-chats/improving-care-options-for-ctcl/48714/Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma and efforts to address those issues.Obesity and Respiratory Function: Understanding Mechanical and Functional Impacts
https://reachmd.com/programs/clinicians-roundtable/obesity-and-respiratory-function-understanding-mechanical-and-functional-impacts/35661/Obesity impacts how the lungs function in a variety of ways, and understanding these impacts is essential for interpreting pulmonary function tests, identifying restrictive or obstructive patterns, and managing ventilation. Learn more with Dr. Sujith Cherian, who's an Associate Professor in the DiviImplementing ACIP's 2025 Flu Vaccine Guidelines Across Patient Populations
https://reachmd.com/programs/vaccination/implementing-acips-2025-flu-vaccine-guidelines-across-patient-populations/36263/As of July 2025, the Advisory Committee on Immunization Practices (ACIP) released new recommendations for influenza vaccination, stating that single-dose thimerosal-free formulations are now required for children up to 18, pregnant individuals, and all adults. While this new guidance may help streng